Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective， Randomized， Open-label， Multicentric，phaseIII Clinical Trial Compared With PC and CEF100 Followed by Docetaxel as Adjuvant Chemotherapy Regimen for Chinese Primary Triple Negative Breast Cancer Patients

NCT01216111 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT01216111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01216111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective， Randomized， Open-label， Multicentric，phaseIII Clinical Trial Compared With PC and CEF100 Followed by Docetaxel as Adjuvant Chemotherapy Regimen for Chinese Primary Triple Negative Breast Cancer Patients
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Completed
Start date
January 1, 2011
Completion date
April 20, 2016
Enrollment
647 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer